作者
Evan J Anderson, Nadine G Rouphael, Alicia T Widge, Lisa A Jackson, Paul C Roberts, Mamodikoe Makhene, James D Chappell, Mark R Denison, Laura J Stevens, Andrea J Pruijssers, Adrian B McDermott, Britta Flach, Bob C Lin, Nicole A Doria-Rose, Sijy O’Dell, Stephen D Schmidt, Kizzmekia S Corbett, Phillip A Swanson, Marcelino Padilla, Kathy M Neuzil, Hamilton Bennett, Brett Leav, Mat Makowski, Jim Albert, Kaitlyn Cross, Venkata Viswanadh Edara, Katharine Floyd, Mehul S Suthar, David R Martinez, Ralph Baric, Wendy Buchanan, Catherine J Luke, Varun K Phadke, Christina A Rostad, Julie E Ledgerwood, Barney S Graham, John H Beigel
发表日期
2020/12/17
期刊
New England Journal of Medicine
卷号
383
期号
25
页码范围
2427-2438
出版商
Massachusetts Medical Society
简介
Background
Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age.
Methods
We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults. The trial was expanded to include 40 older adults, who were stratified according to age (56 to 70 years or ≥71 years). All the participants were assigned sequentially to receive two doses of either 25 μg or 100 μg of vaccine administered 28 days apart.
Results
Solicited adverse events were predominantly mild or moderate in severity and most frequently included fatigue, chills, headache, myalgia, and pain at the …
学术搜索中的文章
EJ Anderson, NG Rouphael, AT Widge, LA Jackson… - New England Journal of Medicine, 2020